All In Biotech

Free tool

FAERS Monitor: Inlexzo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219683 or its brand name (Inlexzo, Gemcitabine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

484

Serious

108

22% of reports

Hospitalization

37

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pollakiuria96
  • dysuria94
  • micturition urgency52
  • urinary tract infection45
  • bladder pain38
  • bladder spasm31
  • haematuria27
  • drug intolerance25
  • pain22
  • product dose omission issue19
  • lower urinary tract symptoms18
  • adverse event15
  • device dislocation15
  • urinary incontinence14
  • bladder irritation12

Reports by year received

View as table
YearReports
202526
2026458

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,675 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lower urinary tract symptomsSignal182276.11429.136,768
bladder irritationSignal12828.6471.38,938
bladder spasmSignal31731.7518.921,535
bladder painSignal38526.4387.219,177
micturition urgencySignal52198.7153.69,993
dysuriaSignal94111.392.810,153
pollakiuriaSignal96100.383.89,333
haematuriaSignal2734.323.8840
urinary incontinenceSignal1420.512.3241
device dislocationSignal1515.09.1183
urinary tract infectionSignal4511.58.7423
drug intoleranceSignal2511.27.7224
adverse eventSignal157.14.373
product dose omission issueSignal192.81.821
pain221.61.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.